Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

Completed · Phase 1

Conditions studied: Pneumonia, Pneumocystis Carinii, HIV Infections

In brief

To determine the safety, tolerance, and pharmacokinetics of a new improved microparticulate suspension formulation of atovaquone administered at one of two dose levels (per 09/30/94 amendment, a third dose level was added) daily for 12 days in HIV-infected and perinatally exposed (per 8/9/95 amendment) infants and children who are at risk of developing Pneumocystis carinii pneumonia (PCP). Atovaquone has shown prophylactic potential in adults in the treatment of PCP but is poorly absorbed in tablet form. To improve the bioavailability of atovaquone, a new formulation has been prepared as a microparticulate suspension. Since studies in adults have demonstrated substantial safety of this drug, evaluation in children is being pursued.

Key facts

Study ID

NCT00000773

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

24

Expected to finish

1996-09-01

Last updated by the study team

2021-10-28

Who can join

Age: 0 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Concurrent Medication:
• Allowed:
• Zidovudine (AZT).
• Dideoxycytidine (zalcitabine; ddC).
• Didanosine (ddI).
• Nonaminoglycoside, nonmacrolide, and nonsulfonamide antibiotics.
• Factor VIII.
• IVIG.
• Patients must have:
• AIDS, documented HIV infection, perinatal exposure to HIV, or risk of developing PCP.
• Normal EKG and chest radiograph.
• No blood or protein on urinalysis.
• Consent of parent or guardian.
• Prior Medication:
• Allowed:
• Prophylactic TMP/SMX if given no less than 3 days prior to study entry.
• Prophylactic aerosolized pentamidine (or a single intravenous dose of 4.0 mg/kg pentamidine) if given no less than 7 days prior to study entry.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Anticipated organ system or laboratory abnormalities (other than immune system abnormalities) from the primary disease and its treatment during the study.
• Acute or chronic infections requiring treatment during the study. NOTE:
• Thrush and herpes labialis are allowed if these conditions do not require treatment.
• Diarrhea or vomiting.
• Concurrent Medication:
• Excluded:
• Trimethoprim/sulfamethoxazole.
• Sulfadoxine and pyrimethamine (Fansidar).
• Primaquine.
• Aspirin.
• Amphotericin B.
• Aminoglycoside antibiotics.
• Sulfonamides.
• Dapsone.
• Benzodiazepines.
• Rifampin.
• Erythromycin, clarithromycin, and azithromycin.
• Digitalis.
• Para-aminosalicylic acid (PAS).
• Isoniazid.
• Anticoagulants.
• Any other investigational therapies.
• Patients with the following prior condition are excluded:

Where it is running

• UCSF Pediatric AIDS CRS — San Francisco, California, United States
• Chicago Children's CRS — Chicago, Illinois, United States
• Tulane/LSU Maternal/Child CRS — New Orleans, Louisiana, United States
• DUMC Ped. CRS — Durham, North Carolina, United States
• St. Jude/UTHSC CRS — Memphis, Tennessee, United States
• Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS — San Juan, Puerto Rico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.